EN DE
Watch Reyon Pharmaceutical Co Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Reyon Pharmaceutical Co Ltd (102460) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Reyon Pharmaceutical Co Ltd stock KRW 9,776, price KRW 9,340, upside +4.7%, quality 34 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7102460003

RP Reyon Pharmaceutical Co Ltd logo Thin data Nov 16, 2026

Reyon Pharmaceutical Co Ltd

102460 · KO

The stock is already about fairly priced, weak company and price moving sideways: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Generates free cash flow over the last twelve months 
Fair value 9,776 KRW · Fairly valued 
Price moving sideways (no uptrend) 
Mixed Growth (revenue 5y +2.3 %/yr in KRW) 
Quality 34/100 
Loss-making · -23.9% net margin (TTM) 
Trails peers (3/11) 
Narrow moat 9/100
Thin data 
Estimate
Watch Reyon Pharmaceutical Co Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

70,413 KRW 9,290 KRW Fair Value 9,776 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 9,290 KRW – 70,413 KRW · fair‑value band 7,332 KRW – 12,220 KRW · the 9,340 KRW price screens below the 9,776 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Reyon Pharmaceutical Co in your weekly email

Every Wednesday you see whether Reyon Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines.

Show moreShow less

The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators.

It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis; VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer; RY103 [NS101], therapeutics antibody for Alzheimer; and RY104, a gene therapy to treat age-related macular degeneration, as well as BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B; RY105, gene therapy to treat liver fibrosis; GB102, for treatment of chronic kidney and coronary artery disease; RY110 which is an iPSC-derived NK cell therapy for solid tumors; RY108, an antifungal drug which is under preclinical study.

In addition, the company engages in the research of RY106/RY107, a mRNA-based virus vaccine and gene therapy for anti-virus and rare genetic diseases; and RY109 which is a pDNA-based cancer vaccine for treatment of Ovarian cancer.

REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.

Stock analysis

Reyon Pharmaceutical Co Ltd (102460) currently trades at 9,340 KRW, while our estimate is 9,776 KRW, so the stock looks roughly fairly valued today (gap 4.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 7,332 KRW (bear) to 12,220 KRW (bull), the price of 9,340 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Reyon Pharmaceutical Co Ltd reported revenue of 146B KRW in FY2025 versus 143B KRW in FY2021, a compound +0.5%/yr. Reported net income was −29.6B KRW in FY2025.

Key figures

Market cap 171B KRW (≈ $129M) Micro · P/S ratio 1.24 · EPS (TTM) −1,867 KRW · Dividend yield 1.5% · Net margin −23.9% · Return on equity −15.9% · Return on assets (EBIT) −0.7% (5-year average) · Operating margin −19.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 26% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 5%, 102460 screens cheaper than that median.

Fair Value

Bear 7,332 KRW Fair Value 9,776 KRW Bull 12,220 KRW
Price 9,340 KRW · Upside +4.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 34
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 31
Debt, balance sheet and risk of trouble
Investment 94
Does it invest with discipline instead of growing at any price?
Low Volatility 79
How calm the share price moves, does not count
Price momentum 28
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 11
Distance to the 52-week high, does not count
New shares 76
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 2/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
Start year 2020 (pandemic)
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.7% (2020) → −21.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 102460, get fair value alerts →

Compare Reyon Pharmaceutical Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside +4.7% · Above median
Profitability
Return on assets −6.4% · Bottom 25%
Net margin (12 months) −23.9% · Bottom 25%
Operating margin (12 months) −19.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −4.9% · Below median
Dividend yield (12 months) 1.5% · Below median
Balance sheet
Debt / equity 0.45× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.78× · Cheapest 25%
P/S (12 months) 1.20× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)40 · sector 20
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)0 · sector 26
HEALTH (low debt)78 · sector 96
DIVIDEND (yield)31 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $85.57 $113.53 +33% vs 102460
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.88 ¥52.43 +12% vs 102460
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,900 ₹1,983 +4% vs 102460
Haleon plc HLN $9.08 $8.47 −7% vs 102460
Merck KGaA MRK €148.40 €108.83 −27% vs 102460
Galderma Group GALD CHF 184.70 CHF 112.46 −39% vs 102460
Takeda Pharmaceutical Company TAK $21.27 $11.23 −47% vs 102460
Sandoz Group SDZ CHF 81.24 CHF 41.06 −49% vs 102460
Teva Pharmaceutical Industries Limited TEVA $42.23 $20.74 −51% vs 102460
Divi's Laboratories Limited DIVISLAB ₹11,178 ₹1,567 −86% vs 102460

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Reyon Pharmaceutical Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Reyon Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/102460

Frequently asked questions

Is Reyon Pharmaceutical Co Ltd (102460) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 9,776 KRW versus a price of 9,340 KRW, about +5% upside (fairly valued).
What is the fair value of 102460?
Our estimate for Reyon Pharmaceutical Co Ltd is 9,776 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 9,340 KRW.
What is the quality score of 102460?
Reyon Pharmaceutical Co Ltd has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Reyon Pharmaceutical Co Ltd (102460)?
We do not set a price target; the yardstick is our estimate of 9,776 KRW (as of Nov 16, 2026). Cautious scenario 7,332 KRW, optimistic scenario 12,220 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Reyon Pharmaceutical Co Ltd stock forecast for 2026?
Our estimate puts fair value at 9,776 KRW, about +5% upside versus a price of 9,340 KRW (fairly valued). Cautious scenario 7,332 KRW, optimistic scenario 12,220 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Reyon Pharmaceutical Co Ltd (102460)?
Reyon Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 143B KRW (latest available figure, as of Nov 16, 2026).
Does Reyon Pharmaceutical Co Ltd pay a dividend?
Reyon Pharmaceutical Co Ltd currently shows a dividend yield of 1.55% relative to its recent price (as of Nov 16, 2026).
How much is the dividend of Reyon Pharmaceutical Co Ltd (102460)?
Reyon Pharmaceutical Co Ltd has a dividend yield of 1.5%.
What is the intrinsic value of Reyon Pharmaceutical Co Ltd (102460)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Reyon Pharmaceutical Co Ltd it is 9,776 KRW per share (as of Nov 16, 2026), against a price of 9,340 KRW.
Is Reyon Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 102460 trades below its calculated fair value: price 9,340 KRW, fair value 9,776 KRW, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 102460?
No. The price is what the market pays today (9,340 KRW); the fair value is what the company's own numbers justify (9,776 KRW). For Reyon Pharmaceutical Co Ltd the two are 435.90 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Reyon Pharmaceutical Co Ltd worth?
The market values Reyon Pharmaceutical Co Ltd at about 171B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 9,340 KRW; our models calculate a fair value of 9,776 KRW per share.
What do the bullish and bearish scenarios say about 102460?
Our models span a range for Reyon Pharmaceutical Co Ltd: cautious scenario 7,332 KRW, base 9,776 KRW, optimistic 12,220 KRW per share (as of Nov 16, 2026, price 9,340 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Reyon Pharmaceutical Co Ltd (102460)?
Balance-sheet figures for Reyon Pharmaceutical Co Ltd (as of Nov 16, 2026): return on equity −15.9%, debt of 0.45 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is 102460 from its 52-week high?
Reyon Pharmaceutical Co Ltd trades at 9,340 KRW, about 26% below its 52-week high of 12,570 KRW and 1% above the low of 9,290 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 9,776 KRW is for.
Which stocks are comparable to Reyon Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Reyon Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price 9,340 KRW, calculated fair value 9,776 KRW (+5%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Reyon Pharmaceutical Co Ltd currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Reyon Pharmaceutical Co Ltd (102460)?
The closing price on Nov 19, 2026 was 9,340 KRW. Our estimate is 9,776 KRW, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Reyon Pharmaceutical Co Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Reyon Pharmaceutical Co Ltd

How large is the market capitalisation of Reyon Pharmaceutical Co Ltd (102460)?
The market capitalisation of Reyon Pharmaceutical Co Ltd is 171B KRW (≈ $129M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Reyon Pharmaceutical Co Ltd (102460)?
The price-to-sales ratio of Reyon Pharmaceutical Co Ltd is 1.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Reyon Pharmaceutical Co Ltd (102460)?
Earnings per share at Reyon Pharmaceutical Co Ltd are −1,867 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Reyon Pharmaceutical Co Ltd (102460)?
The dividend yield of Reyon Pharmaceutical Co Ltd is 1.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Reyon Pharmaceutical Co Ltd (102460)?
The net margin of Reyon Pharmaceutical Co Ltd is −23.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Reyon Pharmaceutical Co Ltd (102460)?
The return on equity (ROE) of Reyon Pharmaceutical Co Ltd is −15.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Reyon Pharmaceutical Co Ltd (102460)?
On an EBIT basis the return on assets of Reyon Pharmaceutical Co Ltd is −0.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Reyon Pharmaceutical Co Ltd (102460)?
The operating margin of Reyon Pharmaceutical Co Ltd is −19.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Reyon Pharmaceutical Co Ltd (102460)?
Revenue at Reyon Pharmaceutical Co Ltd is down 4.9% versus a year earlier (3y avg −1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Reyon Pharmaceutical Co Ltd (102460)?
Earnings per share at Reyon Pharmaceutical Co Ltd are down 21.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Reyon Pharmaceutical Co Ltd (102460) generate?
The free cash flow of Reyon Pharmaceutical Co Ltd is −6.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Reyon Pharmaceutical Co Ltd (102460) carry?
The net debt of Reyon Pharmaceutical Co Ltd is 208B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Reyon Pharmaceutical Co Ltd in the live analysis

One click puts Reyon Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.